$CRME ascending triangle $3.00 Nasdaq GM Webs
Post# of 103030
(Total Views: 260)
Posted On: 02/24/2017 5:42:48 PM
$CRME ascending triangle $3.00
Nasdaq GM
Website
10-Q PDF 11/7/16
Last ten trades
33% x 100% Buy
Low float
Shares Outstanding 31.88M
Float 23.13M
% Held by Insiders 35.64%
% Held by Institutions 19.00%
Shares Short 140.78k
Short Ratio 3.64
Short % of Float 1.67%
Shares Short (prior month) 151.05k
Stock technical analysis
news and filings
Click on 'Investors & Media'
Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of cardiovascular therapies that enhance the life and health of patients suffering from heart diseases. It offers BRINAVESS (vernakalant IV) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. The company also provides ESMOCARD and ESMOCARD LYO short-acting beta-blockers used to control rapid heart rate; and develops TREVYENT for use in treating pulmonary arterial hypertension. It has operations in Canada, the United States, Europe, and internationally. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is based in Vancouver, Canada.
Nasdaq GM
Website
10-Q PDF 11/7/16
Last ten trades
33% x 100% Buy
Low float
Shares Outstanding 31.88M
Float 23.13M
% Held by Insiders 35.64%
% Held by Institutions 19.00%
Shares Short 140.78k
Short Ratio 3.64
Short % of Float 1.67%
Shares Short (prior month) 151.05k
Stock technical analysis
news and filings
Click on 'Investors & Media'
Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of cardiovascular therapies that enhance the life and health of patients suffering from heart diseases. It offers BRINAVESS (vernakalant IV) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. The company also provides ESMOCARD and ESMOCARD LYO short-acting beta-blockers used to control rapid heart rate; and develops TREVYENT for use in treating pulmonary arterial hypertension. It has operations in Canada, the United States, Europe, and internationally. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is based in Vancouver, Canada.
(0)
(0)Scroll down for more posts ▼